GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
GeneDx Holdings Corp. (NASDAQ:WGS) has made the biggest gains on the Russell 2000 Index in 2024 as the biotechnology company moves toward more comprehensive genetic testing.
生物技术公司GeneDx Holdings Corp. (NASDAQ:WGS) 在2024年Russell 2000指数中取得了最大的收益，因为公司正在向更全面的基因检测发展。
The Maryland-based company's shares have soared 1,101% so far this year as of midday Thursday, according to Tradingview.
据Tradingview称，这家总部位于马里兰州的公司股价已在本年度中午之前上涨了1,101%。
Goldman Sachs analyst Matthew Sykes attributes much of GeneDX's positive momentum to shifting its testing. The company went from panel-based tests, which look for variants in more than one gene, to exome/genome testing, which analyzes the bulk of a person's DNA to find genetic variations.
高盛（Goldman Sachs）分析师Matthew Sykes认为，GeneDX的积极势头很大程度上要归功于转变其测试方法。该公司从基于面板的测试转向基因组测试，后者分析一个人大部分的DNA来发现基因变异。
Also Read: GeneDx Stock Climbs After Better-Than-Expected Q1 Results, Raises FY24 Guidance
阅读更多：GeneDx在Q1财报中发布超预期业绩后，股价上涨，提高FY24指引。
"We remain optimistic about WGS's continued focus on converting its mix shift of panel-based tests to whole exome/genome-based tests," Sykes wrote in a note on Wednesday.
Sykes在周三的一份报告中写道：“我们仍然看好WGS继续专注于将面板测试转换为全外显子/基因组测试，”
"As of 1Q24, 30% of their tests were exome/genome-based, whereas this metric was 16% in 1Q23."
“截至2024年第一季度，他们的30%测试是基于全外显子/基因组，而在2023年第一季度，这个指标为16%。”
He said the transition has expanded the company's margins from 33% in the first quarter of 2023 to 61% in this year's first quarter.
他说，这一转变使得该公司的利润率从2023年第一季度的33%提高到今年第一季度的61%。
"We see gross margins continuing to improve going forward, yet see more moderated growth in out years, reaching the mid-high 60% range exiting 2026," he wrote.
他写道：“我们预计毛利率将继续改善，但未来增长将持续缓慢，到2026年，毛利率尚可达到中高60%的水平。”
"We see this mix shift evolution as the key driver of WGS's growth in the near term given their initial focus on rare disease/pediatrics."
他写道：“鉴于他们最初专注于罕见疾病/小儿科，我们认为这种混合转变的进化是WGS短期增长的关键驱动因素。”
Goldman Sachs maintains revenue estimates for GeneDx at $243 million for 2024, $269 million for 2025 and $306 million for 2026. It expects the company to post losses per share of $1.07 for this year and $0.21 for next year and earnings per share of $0.35 for 2026.
高盛维持对GeneDx 2024年的营业收入预期为$24300万，2025年为$26900万，2026年为$30600万。它预计公司今年每股亏损$1.07，明年为$0.21，2026年每股收益为$0.35。
It has given GeneDx a Neutral rating and has increased its price target on the stock from $12.50 to $28.
它给GeneDx股票一个中立评级，并将其股票价格目标从$12.50上调至$28。
Analysts expect GeneDx to post a $0.30 loss per share when it reports second-quarter earnings on July 30, up from a $0.33 loss per share registered for the first quarter, according to Benzinga Pro.
据Benzinga Pro报道，分析师预计GeneDx在7月30日公布第二季度财报时每股亏损$0.30，而第一季度的每股亏损为$0.33。
GeneDx has distanced itself from stocks held by runner-up small-cap companies Massachusetts-based Corbus Holdings Inc. (NASDAQ:CRBP) and Root, Inc. (NASDAQ:ROOT).
GeneDx已与小型公司马萨诸塞州的Corbus Holdings Inc. (NASDAQ:CRBP)和在线汽车保险公司Root, Inc. (NASDAQ:ROOT)保持距离。
Corbus has risen 834% since the beginning of 2024, while Root, an Ohio-based online car insurance company, has gained 670%.
自2024年初以来，Corbus上涨了834%，而总部位于俄亥俄州的在线汽车保险公司Root上涨了670%。
Price Action: GeneDx has slipped 3.36% to $32.18 by Thursday's midday trading, while Corbus has fallen 5.26% to $55.86 and Root has risen 1.49% to $80.59.
GeneDx的股价在周四中午交易时下跌3.36%至$32.18，而Corbus的股价下跌了5.26%至$55.86，Root的股价上涨了1.49%至$80.59。
Other leading small-cap stocks on Russell 2000
Russell 2000指数中的其他领先小市值股票
Below are the remaining companies that round out the top-10 list of top performers in the Russell 2000.
下面是Russell 2000指数中表现最好的前10家公司的列表：
- Elevation Oncology Inc. (NASDAQ:ELEV), up %411%.
- Dave Inc. (NASDAQ:DAVE), up 403%.
- Avidity Biosciences, Inc. (NASDAQ:RNA), up 387%.
- Sezzle Inc. (NASDAQ:SEZL), up 322%.
- Candel Therapeutics, Inc. (NASDAQ:CADL), up 321%.
- NuScale Power Corporation (NYSE:SMR), up 303%.
- Janux Therapeutices, Inc. (NASDAQ:JANX), up 302%.
- Elevation Oncology Inc. (NASDAQ:ELEV)，涨%411。
- Dave Inc.(NASDAQ：DAVE)，涨403%。
- Avidity Biosciences Inc.(NASDAQ: RNA)，涨387%。
- Sezzle公司（纳斯达克：SEZL）涨了322%。
- Candel Therapeutics公司，Inc.（纳斯达克：CADL）涨了321%。
- NuScale Power Corporation公司（纽交所：SMR）涨了303%。
- Janux Therapeutices公司，Inc.（纳斯达克：JANX）涨了302%。
Read Now:
立即阅读：
- Small Cap Stocks Are Having A Moment: Russell 2000 Notches Best 5-Day Rally In Over 4 Years
- 小盘股正迎来大好时机：罗素2000指数创下4年来5天的最佳涨势。
Image: Shutterstock
图片：shutterstock